<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708771</url>
  </required_header>
  <id_info>
    <org_study_id>HSJC-CAR-01-2015</org_study_id>
    <nct_id>NCT02708771</nct_id>
  </id_info>
  <brief_title>Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity</brief_title>
  <acronym>PROTEICA</acronym>
  <official_title>Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Juan de la Cruz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Juan de la Cruz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess whether high doses of ?-3 fatty acids added to standard treatment of patients with&#xD;
      acute hearta failure, hypoalbuminemia and high inflammatory activity, promotes an increase in&#xD;
      serum albumin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess whether high doses of ?-3 fatty acids added to standard treatment of patients with&#xD;
      acute hearta failure, hypoalbuminemia and high inflammatory activity, promotes an increase in&#xD;
      serum albumin&#xD;
&#xD;
      Assess the effect of high doses of ?-3 fatty acids added to standard treatment of patients&#xD;
      with acute hearta failure, hypoalbuminemia and high inflammatory activity on:&#xD;
&#xD;
        -  Inflammatory activity (C-reactive protein)&#xD;
&#xD;
        -  The development of biomarkers (NTproBNP).&#xD;
&#xD;
        -  The prognosis of patients evaluated by the combined event of death from any cause or&#xD;
           readmission for heart failure within three months after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum albumin levels</measure>
    <time_frame>Four weeks</time_frame>
    <description>Serum albumin levels in the fourth week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein levels</measure>
    <time_frame>Four weeks</time_frame>
    <description>C-reactive protein levels in the fourth week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTproBNP levels</measure>
    <time_frame>Four weeks</time_frame>
    <description>NTproBNP levels in the fourth week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined event of death from any cause or readmission for heart failure</measure>
    <time_frame>Three months</time_frame>
    <description>Combined event of death from any cause or readmission for heart failure within three months after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules of similar appearance and flavor without active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyunsaturated fatty acids omega-3</intervention_name>
    <description>4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 daily capsules of similar appearance and flavor without active ingredient</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or olders hospitalized for acute heart failure, chronic&#xD;
             decompensated or new onset of any etiology, presenting hypoalbuminemia (serum albumin&#xD;
             ?3,4 g / dl) and high inflammatory activity (CRP ?2,5 mg / dl).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impending doom&#xD;
&#xD;
          -  Participating in other clinical trials&#xD;
&#xD;
          -  Treatment with ?-3 acids in the last month prior to admission&#xD;
&#xD;
          -  Percutaneous or surgical treatment of the cause of heart failure during&#xD;
             hospitalization.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Renal failure on dialysis.&#xD;
&#xD;
          -  Chronic liver disease Child-Pugh B or C.&#xD;
&#xD;
          -  Acute infectious process.&#xD;
&#xD;
          -  Active malignant neoplasia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital San Juan de la Cruz</name>
      <address>
        <city>Ãšbeda</city>
        <state>Jaen</state>
        <zip>23400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Juan de la Cruz</investigator_affiliation>
    <investigator_full_name>Juan Luis Bonilla Palomas</investigator_full_name>
    <investigator_title>Head of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypoalbuminemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

